Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.
Zhentao YangWei ChenHai ZhuLiang ZhangKe ZhouHong TangRuiqi SunYiqian HuangHaiyang XieShushen ZhenChangku JiaPublished in: Future oncology (London, England) (2022)
Objective: To investigate the prognostic value of DNA methylation of tumor suppressor genes for hepatocellular carcinoma (HCC) recurrence after liver transplantation. Methods: APC gene was selected according to The Cancer Genome Atlas dataset. Tumor tissues and clinical data of 85 HCC patients who received a liver transplantation were retrospectively enrolled and next-generation methylation sequencing was performed. Risk factors were determined using the Cox proportional-hazard-regression model. Results: The APC methylation site (chromosome 5, position 112043544) was an independent predictor of post-transplant HCC recurrence. Patients with hyper-methylated APC 112043544 experienced superior recurrence-free survival (p = 0.021) and had a decreased proportion of microvascular invasion (p = 0.017). APC 112043544 also predicted recurrence risk in patients beyond selection criteria. Conclusions: APC 112043544 methylation may serve as a potential biomarker for post-transplant HCC recurrence.
Keyphrases
- free survival
- genome wide
- dna methylation
- risk factors
- gene expression
- end stage renal disease
- copy number
- ejection fraction
- newly diagnosed
- single cell
- chronic kidney disease
- squamous cell carcinoma
- prognostic factors
- machine learning
- peritoneal dialysis
- patient reported outcomes
- genome wide identification
- transcription factor
- childhood cancer
- genome wide analysis